AbbVie management check
ABBV · Health Care · Biotechnology · CEO Mr. Michael
Filings as of
Closest peers in Biotechnology
- 38GILDGilead Sciences83
- 50VRTXVertex Pharmaceuticals81
- 88REGNRegeneron Pharmaceuticals77
- 111AMGNAmgen76
- 208ABBVAbbVie68
- 300INCYIncyte61
- 405MRNAModerna53
- 439BIIBBiogen48
The seven checks
- GoodBeat its chosen peers
Have owners done well?
What $100 became since fiscal 2021
9977thDetail
$100 invested at the start of fiscal 2021 grew to $259, against $187 for the peer group the company picked itself.
- WatchPay only loosely tracked returns
Does pay follow performance?
Pay actually paid $100 value, each on its own scale
4811thDetail
Over 5 years, the CEO's pay actually paid (equity valued at the share price) had a correlation of -0.03 with shareholder return. 1 means pay moved in step; below 0, the opposite way.
- Good0.8% of net income
What does the CEO cost owners?
$32.5m pay · $4.2bn net income, FY2025
5960thDetail
$32.5m of reported pay in fiscal 2025, against $4.2bn of net income.
- WatchInsiders are selling
Do they own the stock?
6 mo: ▲ $0 bought · ▼ $20.1m sold
——Detail
2 insiders sold $20.1m in the last six months and none bought.
- GoodShare count shrinking
Are owners being diluted?
Diluted shares +0.0% a year; flagged above +2%
Stock pay 1.6% of revenue
5035thDetail
Diluted shares changed +0.0% a year over the last three fiscal years. Stock-based pay was 1.6% of revenue in the latest year.
- Watch2 CEOs in the pay table
Is leadership stable?
7 filings under 8-K 5.02 in 3 years
CEOs: Mr. Michael, Mr. Gonzalez
5025thDetail
CEOs in the pay table: Mr. Michael, Mr. Gonzalez. 7 filings under 8-K item 5.02 (officers or directors leaving or joining, or new pay arrangements) in the last 3 years.
- GoodNo red flags on file
Are the books clean?
Since 2021
- 0Restated
- 0Auditor changes
- 0Late filings
- 010-K amended
100100thDetail
No restatements, auditor changes or late filings since 2021.
Reading the scores
Each check scored 0–100 from its own figure. The tick is the Health Care median; the ordinal is the share of ranked S&P 500 companies it matches or beats.
Hover a chart for its figures. Detail has the full reading.
Pay versus performance
From the proxy statement filed March 23, 2026.
Pay tied most to Adjusted diluted EPS
Other key measuresAdjusted Diluted Earnings Per ShareRelative Return on Invested CapitalAdjusted Return on AssetsNon-GAAP Income Before TaxesNon-GAAP Operating MarginPlatform RevenueTotal Shareholder Return
Show the figures
| Fiscal year | CEO | CEO pay | Actually paid | Other executives (avg) | $100 became | Peers | Net income |
|---|---|---|---|---|---|---|---|
| 2025 | Mr. Michael, Mr. Gonzalez | $32.5m | $57.4m | $12.1m | $259 | $187 | $4.2bn |
| 2024 | — | $28.5m | $67.6m | $11.3m | $195 | $151 | $4.3bn |
| 2023 | — | $25.7m | $34.7m | $12.3m | $164 | $143 | $4.9bn |
| 2022 | — | $26.3m | $67.4m | $9.1m | $164 | $133 | $11.8bn |
| 2021 | — | $23.9m | $66.4m | $11.0m | $132 | $123 | $11.5bn |
Insiders and the CEO's stakeSelling
2 insiders sold $20.1m in the last six months and none bought.
Open-market trades by officers and directors since May 21, 2026.
- SoldJeffrey Ryan StewartEVP, CHIEF COMMERCIAL OFFICER$11.9mNov 9, 2026
- SoldNicholas DonoghoeEVP, CHIEF BUS/STRAT OFFICER$8.2mAug 14, 2026
Leadership and governance on file
All 17 filings
- Nov 2, 2026Leadership change8-K 5.02
- Oct 15, 2026Leadership change8-K 5.02
- May 13, 2025Leadership change8-K 5.02
- Feb 14, 2025Leadership change8-K 5.02
- Dec 13, 2024Leadership change8-K 5.02
- May 8, 2024Leadership change8-K/A 5.02
- Feb 20, 2024Leadership change8-K 5.02
- Oct 12, 2023Leadership change8-K 5.02
- Jun 29, 2023Leadership change8-K 5.02
- Nov 29, 2022Leadership change8-K 5.02
- Oct 17, 2022Leadership change8-K 5.02
- Oct 14, 2022Leadership change8-K 5.02
- Jun 28, 2022Leadership change8-K 5.02
- Apr 13, 2022Leadership change8-K 5.02
- Mar 4, 2022Leadership change8-K 5.02
- Dec 17, 2021Leadership change8-K 5.02
- Dec 16, 2021Leadership change8-K 5.02
Latest shareholder vote results: May 12, 2026, including the say-on-pay vote.
Where the money went
2021–2025: $59.6bn returned to owners in buybacks and dividends, 162% of net income, and $4.0bn of pay in stock.
Show the figures
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | $56.2bn | $58.1bn | $54.3bn | $56.3bn | $61.2bn |
| Net income | $11.5bn | $11.8bn | $4.9bn | $4.3bn | $4.2bn |
| Stock-based pay | $692.0m | $671.0m | $747.0m | $911.0m | $955.0m |
| Buybacks | $934.0m | $1.5bn | $2.0bn | $1.7bn | $980.0m |
| Dividends | $9.3bn | $10.0bn | $10.5bn | $11.0bn | $11.7bn |
| Diluted shares | 1777m | 1778m | 1773m | 1773m | 1773m |
Educational only, not investment advice. Figures are as filed with the SEC: pay from the proxy's pay-versus-performance table, capital allocation from 10-K XBRL data, insider trades from Form 4s over the last six months, events from the last 5 years of filings. The peer group is the one the company chose. See the method.